NASDAQ NMS - GLOBAL MARKET · AMGN

-0.35% · -$1.54 · Vol Not reported

Market closed · last close 4:00 PM ET · price as of 16:00:00 ET

Amgen Inc

Biotechnology

$432.49

Card

Relationship Map

Follow $AMGN

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $AMGN by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET · AMGN

Methodology

AMGN

Amgen Inc

Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET

65/100

Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100

Veridion Score

Upper range · HIGH confidence · 6 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →or $250/yr

Cancel anytime · or Reserve · $79/mo or $790/yr

Confidence: HIGH · 6 of 6 factors measured · Fri Oct 16 · last completed session · Markets closed · resumes Mon 9:30 ET

Share on X →

AI Analysis

Sovereign

Why is AMGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.

Catalyst calendar

What can move AMGN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Sep 22
Congress
David J. Taylor purchase disclosed
STOCK Act filing
Aug 26
Congress
David J. Taylor sale disclosed
STOCK Act filing
Aug 13
Form 4
Khosla Rachna Form 4 sale
SEC Form 4
Aug 12
Congress
Sheldon Whitehouse sale disclosed
STOCK Act filing
Aug 7
Form 4
Miller Derek Form 4 sale
SEC Form 4
Aug 7
Form 4
Grygiel Nancy A. Form 4 sale
SEC Form 4
Jun 5
Congress
David J. Taylor purchase disclosed
STOCK Act filing
Mar 27
Congress
Alan Armstrong sale disclosed
STOCK Act filing
Apr 15
Congress
Tommy Tuberville sale disclosed
STOCK Act filing

About Amgen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1983

Employees

32K

Country

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$437.89

Day high

$438.82

Day low

$431.39

Previous close

$434.03

52W high

$444.12

-2.62% from high

52W low

$291.16

92% of range

Market cap

$233.8B

P/E

26.74×

EPS

$16.10

Beta

0.33

Shares out

540.6M

Avg volume

3.1M

VWAP

$434.03

Last session

Price history computed in-house

+4.25%

+12.15%

+18.76%

+44.74%

YTD

+32.13%

SMA 50 $415.01 · above

SMA 200 $368.90 · above

52W position 92%

AMGN overview

Veridion Score

Registered · 2026-10-16

6 of 6 factors measured

Latest receipt rows

David J. Taylor · Purchase

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around AMGN.Congress disclosuresOpen receipt and filing context for AMGN.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

AMGN insider activity

Amgen Inc

90 days, by filing date. This issuer checked through Oct 18, 2026, 3:36 PM EDT. Published Oct 18, 2026, 3:38 PM EDT.

Score

65 · Upper range

Pressure

Net selling

Open-market Transactions

Filings with trades

Buys / sells

0 / 6

Net value

-$4.1M

Insiders trading

Named filers

Khosla Rachna

SVP, Business Development

Officer

Miller Derek

SVP, Human Resources

Officer

Grygiel Nancy A.

SVP & CCO

Officer

Cluster

No multi-insider purchase cluster in this filing window

Net pressure

Net selling: -$4.1M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Showing 3 of 6 rows.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-13	2026-08-13	Khosla Rachna	SVP, Business Development	sell	$416.43	1,252	6,404	$521K	SEC Form 4
2026-08-13	2026-08-11	Khosla Rachna	SVP, Business Development	sell	$412.57	2,000	6,404	$825K	SEC Form 4
2026-08-07	2026-08-06	Miller Derek	SVP, Human Resources	sell	$402.54	2,069	12,462	$833K	SEC Form 4

Source: SEC EDGAR Form 4. Counts open-market purchases (code P) and sales (code S) only; grants, tax withholding, gifts and option exercises are not counted. Rows with missing price or quantity are excluded rather than zero-filled.Methodology

Public disclosures

Congress activity in AMGN

Congress tracker Open ticker disclosure ledger →

43 filers · 87 buys · 67 sells (6 labeled S (partial)) · Jan 8, 2014 to Sep 22, 2026 · House 121 / Senate 33

All available history · Latest 5 of 154 lines · Read Oct 18, 2026, 9:01 PM UTC

David J. TaylorBuy

Amgen Inc. - Common Stock · Transaction Sep 22, 2026 · Filed Oct 1, 2026 · $1,001 to $15,000

Official filing ↗

David J. TaylorSell

Amgen Inc. - Common Stock · Transaction Aug 26, 2026 · Filed Sep 5, 2026 · $1,001 to $15,000

Official filing ↗

David J. TaylorSell

Amgen Inc. - Common Stock · Transaction Aug 26, 2026 · Filed Sep 5, 2026 · $1,001 to $15,000

Official filing ↗

Sheldon WhitehouseS (partial)spouse

Amgen Inc. - Common Stock · Transaction Aug 12, 2026 · Filed Sep 2, 2026 · $1,001 to $15,000

Official filing ↗

David J. TaylorBuy

Amgen Inc. - Common Stock · Transaction Jun 5, 2026 · Filed Jun 12, 2026 · $1,001 to $15,000

Official filing ↗

See all 154 trades, filters and CSV — Sovereign $25/mo

What Sovereign adds · $25/mo

Every Congress trade, not just the previewFull receipt-linked history for every member, filterable by member, ticker and date.
Filings on the price chartForm 4 and Congress trades marked on the chart, each linked to its source document.
Alerts and watchlists that keep up10 Score alerts by email, 5 watchlists of 50 tickers, and portfolio tracking for 50 positions.

Cancel in one click. 30-day refund on your first annual plan.

Federal contracts

AMGN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed

Refresh interval: 12hSource: Federal contract awards

No federal contracts on file for AMGN in this window.

Lobbying spend

AMGN lobbying filings, year to date.

Registered lobbying filings matched to Amgen Inc.

$8.7M

Refresh interval: 12hSource: LDA disclosure filings

Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)Medicare/Medicaid Health Issues Taxation/Internal Revenue CodeMedicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)

Filing

$3.5M

AMGEN INC

AMGEN, INC.

Jan 20, 2026

Filing

$2.6M

AMGEN INC

AMGEN, INC.

Apr 20, 2026

Filing

$2.4M

AMGEN INC

AMGEN, INC.

Jul 20, 2026

Analyst ratings

Sovereign unlock shows available analyst consensus for AMGN.

Related tickers

Cross-references from this score page.

Apprentice · 1 rail

Similar headline score

Nearest public composite scores. Factor similarity requires Sovereign.

Congress traded this too · AMGN

Trade dates Apr 21, 2026–Oct 18, 2026 · 2 filers · disclosed instruments may differ

David J. TaylorRepublican–OH · 2 buys / 0 sales · latest trade Sep 22, 2026Receipt · filed Oct 1, 2026
Sheldon WhitehouseDemocrat–RI · 0 buys / 1 sales · latest trade Aug 12, 2026Receipt · filed Sep 2, 2026

Accepted first-party filing records · computed Oct 18, 4:58 PM ET.

Keep reading

Computed from served filings. Monthly/week selections use filing dates; stock overlap uses the last 180 trade-date days. Disclosed ranges are not exact trade values.

Most active this month
Gilbert Ray Cisneros, Jr. →
57 receipt-qualified rows filed this UTC calendar month
Receipt · filed Oct 12, 2026
Newest filing
David J. Taylor →
Receipt · filed Oct 15, 2026
Largest disclosed range this week
Scott H. Peters →
$250,001 - $500,000
Receipt · filed Oct 15, 2026
Latest Pelosi filing
Nancy Pelosi →
Receipt · filed Oct 2, 2026
President’s latest served report
Donald J. Trump →
Receipt · filed Sep 25, 2026
Most members trading
MSFT →
12 distinct congressional filers with purchases or sales in the transaction-date 180-day window
Receipt · filed Oct 12, 2026

Accepted first-party filing records · computed Oct 18, 4:58 PM ET.

Follow $AMGN

Why is AMGN moving today?

What can move AMGN next.

AMGN overview

Related filings and maps

AMGN insider activity

AMGN contract awards, year to date.

AMGN lobbying filings, year to date.

Cross-references from this score page.

Congress traded this too · AMGN

What can move AMGN next.

AMGN insider activity

Cross-references from this score page.

Congress traded this too · AMGN